LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Начало・Списък с акции・Corcept Therapeutics Inc

Corcept Therapeutics Inc

Затворен

СекторЗдравеопазване

86.11 1.57

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

85.22

Максимум

86.26

Ключови измерители
By Trading Economics
Приходи	-16M 19M
Продажби	13M 208M
P/E Средно за сектора	91.701 80.03
Марж на печалбата	9.323
Служители	500
EBITDA	-11M 16M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+57.18% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	591M 8.4B
Предишно отваряне	84.54
Предишно затваряне	86.11

Настроения в новините

By Acuity

34%

66%

105 / 374 Класиране в Healthcare

Corcept Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.12.2025 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Brookfield, GIC Agree $4.5 Billion Deal for Australia's National Storage -- Update

5.12.2025 г., 21:08 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms Buys AI-Device Maker Limitless

5.12.2025 г., 19:39 ч. UTC

Значими двигатели на пазара

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5.12.2025 г., 19:17 ч. UTC

Придобивния, сливания и поглъщания

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

7.12.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen -- Market Talk

7.12.2025 г., 23:05 ч. UTC

Пазарно говорене

RBA Set to Remain 'Emphatically' On Hold, Westpac Says -- Market Talk

7.12.2025 г., 22:18 ч. UTC

Пазарно говорене

RBA Set To Conclude Year With Hawkish Message -- Market Talk

6.12.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6.12.2025 г., 10:30 ч. UTC

Придобивния, сливания и поглъщания

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6.12.2025 г., 02:38 ч. UTC

Придобивния, сливания и поглъщания

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5.12.2025 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

5.12.2025 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5.12.2025 г., 21:36 ч. UTC

Пазарно говорене

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5.12.2025 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5.12.2025 г., 21:26 ч. UTC

Придобивния, сливания и поглъщания

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5.12.2025 г., 21:12 ч. UTC

Пазарно говорене

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5.12.2025 г., 21:03 ч. UTC

Пазарно говорене

Печалби

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5.12.2025 г., 21:01 ч. UTC

Пазарно говорене

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5.12.2025 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5.12.2025 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5.12.2025 г., 20:42 ч. UTC

Придобивния, сливания и поглъщания

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5.12.2025 г., 20:01 ч. UTC

Придобивния, сливания и поглъщания

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5.12.2025 г., 19:44 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.12.2025 г., 19:44 ч. UTC

Пазарно говорене

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5.12.2025 г., 19:39 ч. UTC

Пазарно говорене

Silver Climbs to a New Record High -- Market Talk

5.12.2025 г., 19:31 ч. UTC

Придобивния, сливания и поглъщания

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5.12.2025 г., 18:30 ч. UTC

Пазарно говорене

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5.12.2025 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5.12.2025 г., 18:24 ч. UTC

Придобивния, сливания и поглъщания

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Corcept Therapeutics Inc Прогноза

Ценова цел

By TipRanks

57.18% нагоре

12-месечна прогноза

Среден 135.33 USD 57.18%

Висок 145 USD

Нисък 121 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Corcept Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Corcept Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

105 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.